Regulation of plasminogen activator production by bone-resorbing hormones in normal and malignant osteoblasts

J. A. Hamilton, S. Lingelbach, N. C. Partridge, T. J. Martin

Research output: Contribution to journalArticlepeer-review

Abstract

The plasminogen activator (PA) activity of clonal rat osteogenic sarcoma cell (phenotypically osteoblast) and of osteoblast-rich rat calvarial cells is shown to be increased by treatment with the bone-resorbing hormones, PTH, 1, 25-dihydroxyvitamin D3, prostaglandin E2, and epidermal growth factor. Dose-dependent increases were observed, after a lag period of 4 to 8 h. Stimulated and control PA activities were inhibited by actinomycin D and cycloheximide but not by cytosine arabinoside. Glucocorticoid hormones prevented the hormone stimulation, but other steroids did not. Calcitonin had no effect either on basal or on hormone-treated PA activity. Isobutylmethylxanthine alone increased PA activity and enhanced responsiveness to PTH and to prostaglandin E2. These data point to a common pathway in the actions upon osteoblasts of several hormones with diverse initial cellular actions and raise the possibility that the PA/plasmin system may contribute to cellular mechanisms of bone turnover.

Original languageEnglish (US)
Pages (from-to)2186-2191
Number of pages6
JournalEndocrinology
Volume116
Issue number6
DOIs
StatePublished - Jun 1985

ASJC Scopus subject areas

  • Endocrinology

Fingerprint

Dive into the research topics of 'Regulation of plasminogen activator production by bone-resorbing hormones in normal and malignant osteoblasts'. Together they form a unique fingerprint.

Cite this